Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines

• DOI: 10.1016/j.vaccine.2021.01.002
• Publication Date: 2021-01-19T13:47:39Z
• Authors: Rebecca L. Brocato; Steven A. Kwilas; Matthew D. Josleyn; Simon Long; Xiankun Zeng; Casey C. Perley; Lucia M. Principe; Brandon Somerville; Melanie V. Cohen; Jay W. Hooper
• Keywords: 0301 basic medicine; Orthohantavirus; 0303 health sciences; 03 medical and health sciences; Immunogenicity, Vaccine; Cricetinae; Hantavirus Infections; Vaccination; Injections, Jet; Vaccines, DNA; Animals; Viral Vaccines; 3. Good health

AbstractDNA vaccine evaluation in small animals is hampered by low immunogenicity when the vaccines are delivered using a needle and syringe. To overcome this technical hurdle we tested the possibility that a device developed for human intradermal medicine delivery might be adapted to successfully deliver a DNA vaccine to small animals. The PharmaJet®Tropis device is a FDA 510(k)-cleared disposable syringe, needle-free jet injection device designed to administer medicines to the human dermis in a 0.1 mL volume. Here, we found that hantavirus DNA vaccines administered to Syrian hamsters using Tropis were substantially more immunogenic than the same vaccines delivered by needle/syringe or particle mediated epidermal delivery (gene gun) vaccination. By adjusting how the device was used we could deliver vaccine to either subcutaneous tissues, or through the skin into the muscle. RNA and/or antigen expression was detected in epidermal, subepidermal and fibroblast cells. We directly compared six optimized and non-optimized hantavirus DNA vaccines in hamsters. Optimization, including codon-usage and mRNA stability, did not necessarily result in increased immunogenicity for all vaccines tested; however, optimization of the Andes virus (ANDV) DNA vaccine protected vaccinated hamsters from lethal disease. This is the first time active vaccination with an ANDV DNA vaccine has shown protective efficacy in the hamster model. The adaptation of a human intradermal jet injection device for use as a method of subcutaneous and intramuscular jet injection of DNA vaccines will advance the development of nucleic acid based medical countermeasures for diseases modeled in hamsters.